The coronavirus has infected more than three million people across the globe. The death toll has surpassed 200,000 worldwide, according to Johns Hopkins University. In such a scenario, the desperation for a vaccine or treatment is rising by the hour. In fact, according to the latest WHO report, around six vaccine candidates have entered the clinical evaluation stage. These candidates belong to Moderna Inc.MRNA andInovio Pharmaceuticals Inc.(INO) along with China's Sinovac, CanSino Biological Inc., Beijing Institute of Biological Products and University of Oxford. Moreover, around 77 vaccine candidates are under preclinical evaluation, per the report.

Latest Progress in Vaccine Development

Large pharmaceutical player, Johnson & Johnson JNJ has entered into a manufacturing deal with Emergent BioSolutions Inc. (EBS) to strengthen the U.S.-based manufacturing capacity for its COVID-19 vaccine candidate. The company expects to initiate a phase I study on the candidate in September 2020 under an accelerated timeline. Safety and efficacy data from the study is likely to be available by this year-end, based on which, the company expects a vaccine to be available for emergency use in early 2021. Notably, J&J has also identified two back-up candidates apart from the chief COVID-19 candidate.

Moving on, Pfizer PFE and Germany-based biotech BioNTech recently received approval from the local regulatory authority, the Paul-Ehrlich-Institute, to initiate a phase I/II study to evaluate BioNTechs BNT162 vaccine program to prevent COVID-19 infection. They plan to initiate the study shortly. Notably, these companies had signed a deal to co-develop mRNA-based vaccines for COVID-19 last month.

Heating up the competition, pharmaceutical giants Sanofi SNY and GlaxoSmithKline plc GSK joined forces to speed up development of a vaccine for the virus on Apr 14. Both drug makers plan to begin the initial clinical tests of the vaccine prototype in the second half of 2020. The vaccine should be available in the second half of 2021, if the results are positive.

Meanwhile, Novavax has identified a coronavirus vaccine candidate, NVX-CoV2373, and plans to start a first-in-human trial in mid-May. Moderna has initiated a phase 1 trial of COVID-19 vaccine candidate, enrolling subjects at the highest dose. The trial has three arms that are administering doses of 25 mcg, 100 mcg and 250 mcg.

ETFs to Gain

The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that seek to provide exposure to the biotech sector:

iSharesNasdaq Biotechnology ETFIBB

This fund looks to provide exposure to U.S. biotechnology and pharmaceutical stocks and tracks the NASDAQ Biotechnology Index. It comprises 210 holdings. It has AUM of $8.06 billion and charges a fee of 47 basis points a year (read:ETF Strategies to Play the Rising Virus-Induced Volatility).

SPDR S&P Biotech ETFXBI

The fund seeks daily investment results, before fees and expenses, which match the S&PBiotechnology Select IndustryIndex. It holds about 122 securities in its basket. It has AUM of $4.55 billion and an expense ratio of 0.35% (read:6 Top-Ranked ETFs Beating the Market).

VanEck Vectors Biotech ETFBBH

The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 25 securities in its basket. Its AUM is $389.1 million and it has an expense ratio of 0.35%.

Some healthcare ETFs can also be considered:

The Health Care Select Sector SPDR FundXLV

The most popular healthcare ETF, XLV follows the Health Care Select Sector Index. In total, the fund holds 60 securities in its basket, with the pharma sector taking the largest share at 33.2%. Healthcare equipment and supplies, healthcare providers and services, and biotech also have double-digit exposure each. The product manages nearly $24.82 billion in its asset base. The expense ratio is at 0.13% (read:Healthcare ETFs Looks Strong Ahead of Q1 Earnings).

Story continues

Originally posted here:

Healthcare ETFs to Gain on Progress in Coronavirus Vaccine - Yahoo Finance